//
The Regional Government has redistributed budgetary burdens for the acquisition of Eftrenonacog Alfa, ensuring treatment for patients at SESARAM.
The Regional Secretariat for Health and Civil Protection has published Ordinance no. 179/2026, which proceeds with the redistribution and amendment of budgetary burdens for the acquisition of anti-hemorrhagic drugs, specifically the medication Eftrenonacog Alfa, intended for the Health Service of the Autonomous Region of Madeira, EPERAM (SESARAM).
The global base price for the acquisition is 706,212.15 €, plus VAT at a rate of 6%. The financial burden has been fully allocated to the 2026 fiscal year, ensuring the continuity of specialized healthcare required for users of the regional service.
The Madeira Health Service has reallocated its budget for the hospital waste treatment contract and for the acquisition of six vehicles for Home Hospitalization.
A subsidiary and exceptional funding mechanism, up to 2 million euros, has been approved to support intermediate care places for people discharged from hospital for social reasons.
A correction statement has been published to fix a value in the price table for healthcare services in Physical Medicine and Rehabilitation co-funded by the Regional Health Service.